CervoMed’s neflamapimod failed to confirm the primary endpoint in Phase 2b DLB, while exploratory analyses highlighted drug exposure and AD co-pathology.
Written By: Saniya Katakdhond, PharmD
Reviewed By: Pharmacally Editorial Team
CervoMed Inc. announced the publication of two peer-reviewed research articles examining neflamapimod, an investigational oral small-molecule inhibitor of p38α mitogen-activated protein kinase (MAPK), in dementia with Lewy bodies (DLB). The findings include clinical, imaging and mechanistic observations, although the pivotal result remains the failure to confirm the earlier efficacy findings in the overall Phase 2b study population.
The clinical results, published in Alzheimer’s Research & Therapy, came from the 16-week, randomized, double-blind, placebo-controlled phase of the RewinD-LB trial (NCT05869669). The study enrolled 159 participants who received neflamapimod 40 mg three times daily or placebo, followed by a 32-week open-label extension.
Neflamapimod did not demonstrate a significant benefit over placebo on the primary endpoint, change in the Clinical Dementia Rating Sum of Boxes (CDR-SB), in the overall intention-to-treat population. The trial also did not establish significant differences in the secondary clinical outcomes assessed. The findings therefore failed to confirm the efficacy signal reported in the earlier Phase 2a AscenD-LB study.
An MRI substudy involving 18 participants showed a statistically significant increase in right basal forebrain volume with neflamapimod compared with placebo. This structural imaging finding warrants further investigation, but its small sample size and the absence of confirmed clinical benefit mean it cannot independently establish improvement in cognition, daily functioning or disease progression.
Drug Exposure and Alzheimer’s Disease Co-Pathology
Exploratory analyses examined whether treatment response differed according to blood phosphorylated tau 181 (pTau181), a biomarker used to identify participants with a lower likelihood of Alzheimer’s disease (AD) co-pathology.
Among participants with pTau181 levels below 23 pg/mL, the placebo-adjusted difference in CDR-SB was −0.51 points (95% confidence interval [CI], −1.16 to 0.13). For participants with levels below 21 pg/mL, the difference was −0.70 points (95% CI, −1.42 to 0.01). Both estimates favored neflamapimod, but their confidence intervals included zero. These exploratory subgroup findings do not establish a statistically significant treatment benefit or validate pTau181 as a treatment-selection marker.
Drug exposure provided another potential explanation for the results. Participants whose blood neflamapimod concentrations exceeded the study median of 3.64 ng/mL showed CDR-SB treatment effects comparable to those reported in Phase 2a, whereas participants below the median did not show the same pattern.
CervoMed suggested that lower-than-intended exposure associated with the capsule formulation may have contributed to the failure to confirm the earlier findings. However, the observed exposure-response relationship does not prove that formulation-related exposure was the sole cause of the Phase 2b outcome.
The company also reported supportive observations from the 32-week open-label extension, in which participants received neflamapimod without a placebo control. These findings require cautious interpretation, and full extension-phase results are expected in a separate publication.
Neuroinflammatory Findings and Safety
The second publication, in Cells, examined neflamapimod’s effects on inflammatory signaling associated with cognitive decline.
In human peripheral blood mononuclear cells, neflamapimod inhibited interleukin-1 beta (IL-1β)-induced production of interleukin-6 (IL-6) and interleukin-8 (IL-8), with a reported half-maximal effective concentration (EC50) of approximately 3 ng/mL. The company also reported reduced cerebrospinal fluid IL-6 and IL-8 levels in patients with early AD. In patients with DLB, treatment was associated with an increased plasma amyloid-beta 42/40 ratio and reduced plasma glial fibrillary acidic protein levels.
Pharmacokinetic-pharmacodynamic analyses identified a trough plasma concentration of approximately 4 ng/mL associated with pharmacological activity. These mechanistic and biomarker findings characterize the drug’s biological effects but do not establish clinical efficacy in DLB.
During the placebo-controlled phase, adverse-event-related treatment discontinuations occurred in 2.5% of participants receiving neflamapimod and 1.3% receiving placebo. One event considered possibly treatment-related involved transient liver-enzyme elevations in a participant with a pre-existing liver condition. The elevations normalized after treatment discontinuation.
Development Outlook
CervoMed is evaluating a proposed regimen of 100 mg twice daily using a new tablet formulation. The company projects that this regimen could achieve target trough concentrations in more than 90% of participants without substantially increasing peak concentrations or overall drug exposure. This remains a pharmacokinetic projection, not evidence that the proposed regimen will improve clinical outcomes.
The company is seeking a strategic partner to advance neflamapimod into Phase 3 development for DLB. Further evaluation will need to establish whether the tablet formulation improves exposure consistency and whether selecting patients according to AD co-pathology can identify a population more likely to benefit.
Clinical Interpretation
The two publications provide a rationale for continued investigation of neflamapimod, but the failure to confirm the primary endpoint remains the most important clinical finding. The MRI result, subgroup estimates and biomarker changes provide exploratory or supportive signals rather than proof of efficacy or disease modification.
The apparent relationship between drug exposure and clinical outcomes supports further evaluation of the proposed formulation. Similarly, the pTau181 findings raise the possibility that AD co-pathology may influence treatment response, but neither approach has been shown to improve clinical outcomes. A confirmatory Phase 3 trial would be needed to determine whether neflamapimod provides a clinically meaningful benefit in a defined DLB population.
Neflamapimod remains investigational.
Reference
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB). CervoMed Inc., October 29, 2026
Taylor, JP., Alam, J.J., Gomperts, S.N. et al. A phase 2b randomized clinical trial of the oral p38α inhibitor neflamapimod in dementia with Lewy bodies (DLB). Alz Res Therapy (2026). https://doi.org/10.1186/s13195-026-02239-6
RewinD-LB – Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies, ClinicalTrials.gov ID NCT05869669
Alam, J.J.; Germann, U.A.; Maruff, P. Targeting Pro-Inflammatory Interleukin-1 Beta Signaling to Modulate Neuroinflammatory Processes Associated with Cognitive Decline in Dementia with Lewy Bodies. Cells 2026, 15, 1803. https://doi.org/10.3390/cells15191803
About the Writer
Saniya Sanjay Katakdhond (Linkedin) is a Doctor of Pharmacy professional with hands-on experience in patient case review, clinical documentation, medical record analysis, and patient care.
Her hospital experience has strengthened her understanding of clinical conditions, treatment approaches, and multidisciplinary healthcare practices.
With ICH-GCP certification and a research-oriented approach, she brings clinical insight and attention to detail to healthcare content development.
As a healthcare writer, Saniya focuses on translating clinical knowledge and patient-care experience into clear, accurate, and evidence-informed medical content.